Automatic oxygen titration with O2matic® to patients admitted with COVID-19 and hypoxemic respiratory failure.

Introduction: Patients with coronavirus disease (COVID-19) and pneumonitis often have hypoxemic respiratory failure and a need of supplementary oxygen. Guidelines recommend controlled oxygen, for most patients with a recommended interval of SpO between 92 and 96%. We aimed to determine if closed-loop control of oxygen was feasible in patients with COVID-19 and could maintain SpO in the specified interval.

TOB-STOP-COP (TOBacco STOP in COPd trial): study protocol-a randomized open-label, superiority, multicenter, two-arm intervention study of the effect of "high-intensity" vs. "low-intensity" smoking cessation intervention in active smokers with chronic obstructive pulmonary disease.

Background: Cigarette smoking is the leading cause of chronic obstructive pulmonary disease (COPD), and it contributes to the development of many other serious diseases. Smoking cessation in COPD patients is known to improve survival and reduce the number of hospitalization-requiring acute exacerbations of COPD. However, smoking cessation interventions in these patients have only been successful for approximately 15-20% for consistent smoking abstinence in 12 months.

Automated oxygen control with O2matic during admission with exacerbation of COPD.

Purpose: It is a challenge to control oxygen saturation (SpO) in patients with exacerbations of COPD during admission. We tested a newly developed closed-loop system, O2matic, and its ability to keep SpO within a specified interval compared with manual control by nursing staff.

Patients And Methods: We conducted a crossover trial with patients admitted with an exacerbation of COPD and hypoxemia (SpO ≤88% on room air).